#United States #New York #Securities Fraud #Rosen Law Firm #Biohaven Ltd

Investors Invited to Participate in Biohaven Ltd. Class Action

Attention all investors of Biohaven Ltd. (NYSE: BHVN)! If you acquired securities from March 24, 2023, to May 14, 2025, you might have grounds to take legal action following allegations of securities fraud. Rosen Law Firm, a reputable global player in investor rights law, is urging those affected to join a class action lawsuit concerning Biohaven Ltd.

Key Dates and Information

The deadline to file to be a lead plaintiff is approaching on September 12, 2025. Should you choose to take part in this action, you could claim compensation without incurring upfront costs, thanks to a contingency fee arrangement. This means you’re only charged if the case is successful, providing a safety net for those who have incurred losses.

How to Join the Action

To join this class action lawsuit, potential plaintiffs can conveniently visit Rosen Law Firm's submission page or directly reach out to attorney Phillip Kim at 866-767-3653. This is a crucial step, especially for those wanting to serve as a lead plaintiff, a role which represents the interests of all involved parties in the ongoing litigation.

Understanding the Allegations

Rosen Law Firm is particularly noted for its successful record in securities class actions. Several allegations arise from the following claims made against Biohaven Ltd. during the class period:

• - Misrepresentation of Drug Efficacy: Defendants purportedly misled investors regarding the regulatory prospects of their product, troriluzole, for treating spinocerebellar ataxia (SCA). The perceived advantages and the data submitted to support its approval were claimed to be overstated.
• - Overstated Clinical Trials: Claims concerning another product, BHV-7000, and its effectiveness in treating bipolar disorder were similarly exaggerated. This misrepresentation could lead to severe repercussions for Biohaven's business and financial health once the truth surfaced.
• - Market Reaction and Damages: The lawsuit underscores that when the true circumstances came to light, many investors faced significant financial losses as the implications for Biohaven materialized in the market.

Selecting Your Legal Representation

When selecting legal counsel, Rosen Law Firm implores interested investors to work with qualified attorneys with a proven success record in similar cases. Many firms may send out notices but lack the appropriate resources, experience, or recognition needed to effectively handle securities class actions. Therefore, it’s pivotal to do thorough research before making your choice of representation.

Rosen Law Firm’s Track Record

Rosen Law Firm has secured numerous settlements over the years, including the largest ever for a securities class action related to a Chinese company at one point. From 2013, they consistently ranked among the top firms handling securities class action settlements and reclaimed hundreds of millions in losses for investors across various cases. Remarkably, in just one year, they successfully recovered over $438 million for affected investors.

Additionally, Lawrence Rosen, the founding partner, was recognized by Law360 as a Titan of the Plaintiffs' Bar in 2020, affirming the firm’s capabilities and dedication to protecting investor rights.

Conclusion

Don’t miss your chance to take action if you purchased Biohaven securities during the specified period. Make sure to stay informed and make a choice by the deadline. For further inquiries, feel free to connect with Rosen Law Firm through their official communication channels. Follow them on LinkedIn, Twitter, and Facebook for ongoing updates about the case and other relevant news. Remember, your voice as an investor matters.